Cargando…

Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957

Detalles Bibliográficos
Autores principales:	Gan, Sushrima, Dawed, Adem Y., Donnelly, Louise A., Nair, Anand T.N., Palmer, Colin N.A., Mohan, Viswanathan, Pearson, Ewan R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2020
Materias:	e-Letters: Comments and Responses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770275/ https://www.ncbi.nlm.nih.gov/pubmed/33218985 http://dx.doi.org/10.2337/dci20-0049

Ejemplares similares

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Gan, Sushrima, et al.
Publicado: (2020)

Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study
por: Newman, Terri Victoria, et al.
Publicado: (2021)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
por: Trombara, Filippo, et al.
Publicado: (2023)

FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment
por: Jain, Arad, et al.
Publicado: (2023)

Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
por: Chadha, Manoj, et al.
Publicado: (2022)

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
por: Anson, Matthew, et al.
Publicado: (2023)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Koike, Masao, et al.
Publicado: (2021)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Kim, Dae H, et al.
Publicado: (2019)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
por: Du, Lixin, et al.
Publicado: (2022)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

The impact of phenotype, ethnicity and genotype on progression of type 2 diabetes mellitus
por: Thakarakkattil Narayanan Nair, Anand, et al.
Publicado: (2020)

Patients’ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation
por: Costa Gil, José Esteban, et al.
Publicado: (2022)

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
por: Morton, Jedidiah I., et al.
Publicado: (2022)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
por: Belli, Martina, et al.
Publicado: (2022)

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials: Perspective on GLP-1 RA and SGLT-2i therapies
por: Ludwig, Lisa, et al.
Publicado: (2020)

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
por: D'Marco, Luis, et al.
Publicado: (2021)

Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors
por: Young, Katherine G, et al.
Publicado: (2023)

Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review
por: Young, Katherine G., et al.
Publicado: (2023)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
por: Luo, Jing, et al.
Publicado: (2023)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Comment on Löndahl. Number Eight in the Service of Diabetic Foot Ulcer Healing. Diabetes Care 2020;43:515–517
por: Frykberg, Robert G.
Publicado: (2020)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients
por: Lu, Yang, et al.
Publicado: (2023)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
por: Wołos-Kłosowicz, Katarzyna, et al.
Publicado: (2022)

Response to Comment on Piccinini and Bergman The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Bergman, Richard N., et al.
Publicado: (2021)

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
por: Knudsen, Jakob S., et al.
Publicado: (2020)

Diabetic Euglycemic Ketoacidosis Induced by Oral Antidiabetics Type SGLT2i
por: Velasco de Cos, Guillermo, et al.
Publicado: (2021)

Erratum. Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care 2020;43:90–97
por: Hampp, Christian, et al.
Publicado: (2020)

Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”
por: Zhu, Hengliang, et al.
Publicado: (2022)

The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
por: Pan, Xiaohui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_goheqrpbiii5idfp9h6ehc63cg